Drug Profile
Rubitecan liposomal
Alternative Names: 9-Nitrocamptothecin liposomal; Inhaled rubitecan; Rubitecan - Clayton Foundation for Research/SuperGen; Rubitecan liposomal aerosolLatest Information Update: 12 Apr 2007
Price :
$50
*
At a glance
- Originator Clayton Foundation for Research
- Class Antineoplastics; Camptothecins; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors; DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer metastases; Lung cancer
Most Recent Events
- 12 Apr 2007 Discontinued - Phase-I for Lung cancer in USA (Inhalation)
- 12 Apr 2007 Discontinued - Phase-II for Cancer metastases in USA (Inhalation)
- 27 Nov 2003 Phase-II clinical trials in Cancer metastases in USA (Inhalation)